Document:

Exhibit 10.9

 

Portions herein identified by [*****] have
been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

SETTLEMENT
AND RELEASE AGREEMENT

 

This
Settlement and Release Agreement (“Agreement”) is made and entered into this 11th day of May, 2017, between Icagen,
Inc. f/k/a Caldera Pharmaceuticals, Inc. (“Icagen”) and Dentons US LLP (“Dentons”). Icagen and Dentons
may be referred to herein individually as a “Party” or collectively as the “Parties.”

 

WHEREAS,
Dentons previously provided legal services to Icagen ( the “Representation”), including in connection with litigation
commenced by Icagen against the Regents of the University of California and/or related parties;

 

WHEREAS,
following disputes between them, Dentons and Icagen entered into a Settlement and Release Agreement (the "2013 Settlement
Agreement"), a copy of which is attached as Exhibit A, fully and finally resolving any and all claims and potential
claims arising out of, based upon, or relating to the Representation;

 

WHEREAS,
Icagen did not make any payment to Dentons under the 2013 Settlement Agreement;

 

WHEREAS
on April 22, 2014, Dentons filed a complaint in the Circuit Court of Cook County, Illinois, captioned Dentons vs. Caldera Pharmaceuticals,
Inc. bearing docket number 14 L 50351, seeking entry of a judgment by confession against Icagen (the “Illinois Lawsuit”)
based upon the 2013 Settlement Agreement.

 

WHEREAS,
on May 7, 2014, a judgment was entered in the Illinois Lawsuit in favor of Dentons and against Icagen, in the amount of three
million and fifty thousand dollars ($3,050,000.00) plus costs of suit (the “Judgment”), a copy of which is attached
as Exhibit B, which Judgment remains outstanding;

 

WHEREAS,
Icagen filed the following lawsuits against Dentons in San Francisco Superior Court (collectively, the "California Lawsuits"):
(1) an action styled Richard Roe, et al. v. White Corporation, et al., bearing docket no. 14 CGC 538762, which action was
dismissed without prejudice; (2) an action styled Richard Roe, et al. v. White Corporation, et al., bearing docket no.
15 CGC 544238, which action was dismissed without prejudice; and (3) an action styled Richard Roe, et al. v. White Corporation,
et al., bearing docket no. 17 CGC 558125, which remains pending;

 

WHEREAS,
the Parties now desire to fully and finally settle any and all claims and potential claims arising out of, based upon, or relating
to the 2013 Settlement Agreement, the Illinois Lawsuit, the Judgment, and the California Lawsuits;

 

NOW,
THEREFORE, in consideration of the mutual covenants, conditions and promises contained herein, and other good and valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows:

 

1.            Payment.
Icagen shall pay Dentons the sum of One Million Four Hundred Thousand Dollars ($1,400,000.00) as follows:

 

(a)
       $250,000 to be received by Dentons no later than May 15, 2017;

 

     

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(b)
       $250,000 to be received by Dentons no later than June 1, 2017 or the date of the closing
of Icagen's pending debt financing, whichever is sooner;

 

[*****]

 

All
sums paid herein shall paid by wire transfer directed to:

 

[*****]

 

2.           
Security. Simultaneous with the execution of this Agreement, Icagen shall execute and deliver to Dentons an ink
original Affidavit in Support of Confession of Judgment in the amount of $3,891,549.32 (i.e., the amount of the Judgment plus
costs of suit plus accrued interest through May 15, 2017) and in the form annexed hereto as Exhibit C (the “Confession of
Judgment”). Upon collection of full payment in accordance with Paragraph 1 of this Agreement, Dentons shall return the ink
original Confession of Judgment to Icagen. If Dentons fails to timely receive, when due, any of the payments in accordance with
Paragraph 1, then Icagen shall be in default of the Agreement (“Default”) and shall have five (5) business days from
the delivery of the notice to cure the Default. Notice shall be delivered by (i) a nationally recognized next day courier service,
or (ii) first class registered or certified mail, postage prepaid. Notices hereunder shall be delivered to:

 

Mr.
Richard Cunningham

Icagen, Inc.

4222 Emperor Blvd, Suite 350

Durham, NC 27703

 

With
a copy to:

 

Leslie
Marlow

Gracin & Marlow LLP

405 Lexington Avenue, 26th Floor

New York, New York 10174

 

Failure
by Icagen to cure the Default within five (5) business days from delivery of notice of the Default shall result in the immediate
right of Dentons to file the Confession of Judgment upon an affidavit or affirmation of noncompliance in a court of competent
jurisdiction, in the amount of $3,891,549.32 plus accrued statutory interest subsequent to May 15, 2017, less any payments made
subsequent to the execution of this Agreement and through the date of Default, plus interest.

 

3.             Existing
Pleadings/Judgment.

 

(a)       Within
five (5) business days following execution of this Agreement, Icagen will discontinue or dismiss the California Lawsuits with
prejudice and will provide Dentons with Filed-stamped copies demonstrating such dismissal or discontinuance with prejudice. Icagen
represents that it has not filed any other claims or proceedings against Dentons.

 

    	 	2	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(b)       Within
five (5) business days following receipt of the payments in accordance with Paragraphs 1(a) and (b) herein (i.e., following timely
receipt by Dentons from Icagen of payments of no less than $500,000), either Party shall file an agreed motion in the Circuit
Court of Cook County, Illinois in the Illinois Lawsuit seeking (i) to vacate the Judgment of May 7, 2014; (ii) to dismiss the
Illinois Lawsuit with prejudice; (iii) the entry of an agreed order in the form attached hereto as Exhibit D (“Agreed
Order”) and (iv) the Court’s approval of a Release of Judgment in the form attached hereto as Exhibit E (“Release
of Judgment. Dentons agrees to furnish Icagen with a signed Agreed Order and two signed ink originals of the Release of Judgment
within five (5) business days following receipt of the payments from Icagen under paragraphs 1(a) and 1(b) of this Agreement.

 

(c)       Dentons
represents that it has not filed any claims, proceedings or judgments against Icagen other than the Illinois Litigation.

 

(d)       Nothing
herein shall prejudice Dentons’ right, in the event of Icagen's breach of this Agreement, to file the Confession of Judgment
as set forth in paragraph 2, above.

 

4.           
Full and Complete Settlement. The Parties agree that this Agreement and the terms set forth herein, shall and hereby
do effectuate a full and complete settlement of all claims and potential claims arising out of, based upon, or relating to the
2013 Settlement Agreement, the Illinois Lawsuit, the Judgment and the California Lawsuits (collectively, the “Released Claims”).
For avoidance of doubt, the 2013 Settlement Agreement shall remain in full force and effect, except that the Parties shall have
no further rights or obligations under paragraphs 1 through 4 thereof, which are superceded by the provisions of this Agreement.

 

5.            Mutual
Releases.

 

(a)       [*****]

 

6.            Unknown
Claims. The Parties acknowledge and understand that there is a risk that, subsequent to the execution of this Agreement,
they may discover, incur or suffer Released Claims which were unknown or unanticipated at the time of the execution of this Agreement,
and which if known on the date of the execution of this Agreement might have materially affected their decision to enter into
and execute this Agreement. The Parties further agree that, by reason of the release contained herein, they are assuming the risk
of such unknown Released Claims and agree that this Agreement applies thereto.

 

7.            Forbearance
From Suit.

 

(a)       Icagen,
and all persons acting by, through, under or in concert with it, hereby promise, covenant and agree not to initiate, file or otherwise
commence, assert, bring, join, participate in, or otherwise maintain against the Dentons Released Parties, in any court, agency,
or other tribunal in any jurisdiction, either directly or indirectly, any claim which they now have, own or hold or claim to have,
own or hold, or at any time heretofore had, owned or held, or claimed to have had, owned or held, or may hereinafter have, own
or hold, or claim to have, own or hold against the Dentons Released Parties, arising out of, based upon, or relating to the Released
Claims.

 

    	 	3	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

(b)       Dentons,
and all persons acting by, through, under or in concert with it, hereby promise, covenant and agree not to initiate, file or otherwise
commence, assert, bring, join, participate in, or otherwise maintain against the Icagen Released Parties, in any court, agency,
or other tribunal in any jurisdiction, either directly or indirectly, any claim which they now have, own or hold or claim to have,
own or hold, or at any time heretofore had, owned or held, or claimed to have had, owned or held, or may hereinafter have, own
or hold, or claim to have, own or hold against the Icagen Released Parties, arising out of, based upon, or relating to the Released
Claims.

 

8.           Cal.
Civ. Code Section 1542. The parties specifically acknowledges that they are aware of and familiar with the provisions
of California Civil Code Section 1542, which provides as follows:

 

“A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME
OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

 

Being
aware of this section, the Parties hereby expressly waive and relinquish all rights and benefits they may have pursuant to said
Code Section as well as any other statutes or common law principles of similar effect.

 

9.          Compromise.
The Parties agree that this Agreement is in compromise and settlement of a dispute between them, and it shall not be considered
as an admission of the truth or correctness of any claim allegation against them, or of fault or liability by them, each Party
denying any fault or liability, except that Icagen acknowledges that it has not disputed, and will not dispute, that Dentons properly
obtained the Judgment against it.

 

10.       Full
and Independent Knowledge. Each of the Parties represents that it has been represented by separate counsel of its choice
in connection with the preparation and review of this Agreement, its representative has specifically discussed, or had the opportunity
to specifically discuss, with such attorney the meaning and effect of this Agreement, and that its representative has carefully
read and understands the scope and effect of each provision contained herein. Dentons has not represented, advised, or served
as Icagen's counsel in connection with this Agreement.

 

11.       Warranties.
Each of the Parties represents and warrants that it has full power and authority to enter into and perform this Agreement.
Each of the Parties further represents and warrants that it has not heretofore assigned, transferred, encumbered or otherwise
conveyed, or purported to assign, transfer, encumber or otherwise convey, in whole or in part, to any person or entity, any Released
Claims released hereunder.

 

12.       Confidentiality.
Except to the extent necessary to enforce or carry out this Agreement or as otherwise required by law, the Parties shall maintain
the terms and existence of this Agreement strictly confidential. Prior to responding to any request, subpoena, or order by any
court or governmental agency for disclosure of this Agreement and/or the compromise and settlement effected thereby, the Party
to which the request, subpoena, or order has been directed shall notify all other Parties, in writing, within seven (7) days of
such request, subpoena, or order and to afford those Parties the opportunity to object to the request, subpoena, or order before
responding thereto. Notwithstanding the foregoing: [*****]; (b) the Parties shall have the right to disclose the terms of this
Agreement to the extent necessary to comply with their financial, legal, reporting, regulatory and securities obligations, including,
to the extent that Icagen concludes that such filing is required, the filing of this Agreement as an exhibit to Icagen’s
periodic filings with the Securities and Exchange Commission, provided, however, that Icagen will request confidential treatment
of certain non-financial terms of the Agreement based on input from Dentons; (c) the Parties may disclose this Agreement to their
attorneys, accountants, financial advisors, bankers, financiers, and potential and actual investors, provided such individuals
are made aware of this Confidentiality provision and agree to be bound thereby.

 

    	 	4	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

13.           Successors.
This Agreement shall be binding upon and inure to the benefit of the successors, heirs and assigns of each of the Parties
hereto.

 

		14.	Miscellaneous.

 

(a)       This
Agreement shall be construed in accordance with and governed by the laws of the State of Illinois, United States of America, without
regard to conflict of laws provisions. The Parties agree that the sole venue for disputes arising out of, related to and/or connected
with this Agreement shall be the state courts situated in Cook County, Illinois.

 

(b)       The
Parties agree that this Agreement may be executed in counterparts and that a copy signed by a Party will be fully enforceable
against such Party. Unless an ink original is required herein (e.g. the Release of Judgment and the Confession of Judgment), this
Agreement, and documents relating to this Agreement, may be executed and transmitted by facsimile, email or any other electronic
means.

 

(c)       This
document contains the entire agreement between the Parties hereto with respect to the subject matter hereof, and supersedes and
cancels all previous agreements, contracts, covenants, commitments, obligations, and writings between the parties pertaining to
the subject matter hereof. Each of the Parties further represents that no other understandings, statements, promises, or inducements
contrary to the terms of this Agreement, whether oral or written, exist, and that he/it does not rely and has not relied upon
any representation or statement made by another Party or any of their representatives with regard to the subject matter of this
Agreement (other than those representations and statements made in this Agreement).

 

(d)       This
Agreement shall be construed as a whole, according to its fair meaning, and shall not be construed strictly for or against any
of the Parties hereto.

 

(e)       This
Agreement may not be amended, altered, modified or waived, in whole or in part, except in a writing executed by the Parties to
this Agreement.

 

(f)       If
any provision of this Agreement is held invalid or otherwise unenforceable, the enforceability of the remaining provisions shall
not be impaired thereby.

 

(g)       The
failure of any Party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver
thereof or deprive that Party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.

 

    	 	5	 

    Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.

    

 

IN
WITNESS WHEREOF, the Parties have each executed this Agreement as of the date first set forth above.

 

	ICAGEN, INC. f/k/a	 	DENTONS US LLP
	CALDERA PHARMACEUTICALS, INC.	 	 	 
	 	 	 	 	 
	By:	/s/
    Richard Cunningham	 	By:	/s/
    Edward J. Reich
	Title:	Chief
    Executive Officer	 	Title:	U.S.
    General Counsel and Partner
	 	 	 	 	 
	Agreed
    as to form:	 	 	 
	 	 	 	 
	BLUMENTHAL
    LAW GROUP P.C.	 	 	 
	 	 	 	 	 
	By:	Grant
    Blumenthal	 	 	 
	Title:	Counsel
    for Icagen, Inc. f/k/a	 	 	 
	 	Caldera
    Pharmaceuticals, Inc.	 	 	 

 

    	 	6	 

     

    

 

EXHIBIT A

 

[*****]

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	A-1	 

     

    

 

EXHIBIT B

 

IN THE CIRCUIT COURT OF COOK COUNTY, ILLINOIS

 

	DENTONS
        US LLP,

         

        Plaintiff,

         

        vs.

         

        CALDERA PHARMACEUTICALS, INC.,

         

        Defendant.
	)

        )

        )
        Case No. 14L50351

        )

        )

        )

        )

        )

        )

        )

 

JUDGMENT ORDER

 

It is ordered that
plaintiff Dentons US LLP recover from defendant Caldera Pharmaceuticals, Inc.  $3,050,000 and costs
of suit. Execution may issue.

 

Plaintiff may withdraw the original documents upon filing certified
copies with the clerk.

 

	 	_________________________, ________________
	 	 
	 	ENTER:
	 	 
	 	/s/ Doruthy Brown
	 	Judge                                                        Judge’s
    No.

 

 

	 

                           Atty.
                           No.: 6205749

Name: Andrew R. McGaan

Atty. for: Dentons US LLP

Address: 300 N. LaSalle St.

City/State/Zip: Chicago,
IL 60654

Telephone: 312-862-2000

	 

 

    	 	B-1	 

     

    

 

EXHIBIT C

 

	DENTONS
        US LLP,

         

        Plaintiff,

         

        vs.

         

        ICAGEN,
        INC. f/k/a CALDERA

        PHARMACEUTICALS,
        INC.,

         

        Defendant.
	)

        )

        )
        Case No. _______

        )

        )

        )
        AFFIDAVIT OF RICHARD CUNNINGHAM

        )

        )

        )

        )

 

RICHARD
CUNNINGHAM, under penalty of perjury, hereby swears that the following information is true and correct to the best of my knowledge
and information:

 

1.       I
am the CEO and President of defendant Icagen, Inc. f/k/a Caldera Pharmaceuticals, Inc. (“Icagen”). Icagen is a Delaware
corporation having its principal place of business at 4222 Emperor Blvd., Suite 350, Research Triangle Park, Durham, North Carolina
27703.

 

2.       I
make this Affidavit in connection with a certain agreement dated May __, 2017 (“the Agreement”) between Icagen and plaintiff
Dentons US LLP (“Dentons”) to confess judgment on behalf of Icagen in this Court in favor of plaintiff for the sum of
three million eight hundred and ninety-one thousand five hundred and forty nine dollars and thirty two cents ($3,891,549.32),
less any amounts paid pursuant to the Agreement, and to authorize Dentons to enter judgment for that sum against Icagen in this
Court.

 

    	 	C-1	 

     

    

 

3.       This
Confession of Judgment is for a debt justly due to Dentons pursuant to a 2013 Settlement
Agreement between Dentons and Icagen, and a Judgment entered pursuant thereto in the amount of three million and fifty
thousand dollars ($3,050,000), plus costs of suit and interest, which resolved Dentons’ claim for fees and disbursements owed
for professional services rendered to Icagen from 2011 through July 5, 2013. Pursuant to the Agreement, Dentons has agreed to
compromise the amounts due and accept, inter alia, payment in the amount of one million four hundred thousand dollars
($1,400,000.00), to be paid pursuant to a schedule set forth therein.

 

4.       In
the event Icagen defaults in making any payment set forth in the Agreement on a timely basis, Dentons is required to give Icagen
written notice of such default.

 

5.       If
Icagen fails to cure said default within five (5) business days after notice is delivered as required by the Agreement, Icagen
shall immediately become obligated to Dentons for the full three million eight hundred and ninety one thousand five hundred and
forty nine dollars and thirty cents ($3,891,549.32), less any amounts paid pursuant to the Agreement.

 

6.       If
Icagen fails to cure the default within five (5) business days after notice is delivered in accordance with the Agreement, Icagen
hereby irrevocably confesses judgment in favor of Dentons for the full three million eight hundred and ninety-one thousand five
hundred and forty-nine dollars and thirty cents ($3,891,549.32), less any amounts paid pursuant to the Agreement.

 

    	 	C-2	 

     

    

 

7.       Accordingly,
if Icagen fails to cure the default within five (5) business days after notice is delivered in accordance with the
Agreement, judgment may be entered hereunder against Icagen, Inc. f/k/a Caldera Pharmaceuticals, Inc. and in favor of Dentons
US LLP in the amount of three million eight hundred and ninety-one thousand five hundred and forty-nine dollars and thirty
cents ($3,891,549.32), less any amounts paid pursuant to the Agreement, plus court filing fees, upon the filing of this
Affidavit together with an Affidavit from a representative of Dentons stating that payment required by the Agreement was not
timely made and setting forth the full amount then due, including the basis for calculation, plus court filing
fees.

 

FURTHER,
AFFIANT SAYETH NOT.

 

	 	/s/
    Richard
    Cunningham 
	 	Richard
    Cunningham

 

	
        SUBSCRIBE and SWORN to before

        me this 11th May, 2017
	 
	 	
        

	/s/ James O. Whitmore
	Notary Public

 

    	 	C-3	 

     

    

 

EXHIBIT
D

 

IN
THE CIRCUIT COURT OF COOK COUNTY, ILLINOIS

 

	DENTONS
        LLP

                                                                                                  

                                                                                                 vs

         

        CALDERA
        PHARMACEUTICALS, INC

n/k/a ICAGEN, INC
	)

        )

        )
No. 14 L 50351

        )

        )

        )

 

AGREED
ORDER TO VACATE JUDGMENT

AND DISMISS WITH PREJUDICE 

 

This matter before the Court on the Agreed
Motion of Dentons LLP and Caldera Pharmaceuticals, Inc n/k/a Icagen, Inc, due notice given and the Court and parties being fully
advised in the premises, it is hereby ordered that:

 

		1.	The
                                         Judgment of May 7, 2014, in the amount of $3,050,00.00 plus costs of suit is hereby

                                         vacated.
	 	 	 

		2.	This
                                         matter is dismissed with prejudice with each side to bear their own attorneys’ fees and
                                         costs.

 

	AGREED:			
		Dentons LLP,	 	Caldera Pharmaceuticals, Inc
	 	By
its counsel of record	 	n/k/a
                   Icagen, Inc, by its counsel of record

 

	Date:		 	
	 	 	 	 
	 	 	 	ENTER:	
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	Judge Judge’s No.

 

__________________(No.______________)

Dentons
LLP

300
N. LaSalle Street

Chicago, Illinois 60654

Tel: (312) 862-2000

 

    	 	D-1	 

     

    

 

EXHIBIT
E

 

	IN THE CIRCUIT COURT OF
 COOK COUNTY, ILLINOIS

                        

                       Dentons,
LLP

                        

                       v.

 

Caldera
Pharmaceuticals, Inc.

k/n/a
Icagen, Inc.
		
	 	 	 
	 	 	Recorder’s
Stamp
	 	 	 
	 	 	                       No. 14 L 50351

 

RELEASE
OF JUDGMENT

 

Dentons, LLP, the Judgment Creditor, having received full consideration
for this release, releases the judgment entered on May 7, 2014, against Defendant, Caldera Pharmaceuticals Inc., k/n/a Icagen,
Inc. for $3,050,000.00.

 

	 	
		Attorney of Record for Dentons, LLP

 

		APPROVED:	
	 	 	Judge                   Judge’s No.

 

__________________ (No.__________________)

Dentons
LLP

300
N. LaSalle Street

Chicago, Illinois 60654

Tel: (312) 862-2000

 

 

 

E-1EX-4.1

 EXHIBIT 4.1 

CITIBANK CREDIT CARD ISSUANCE TRUST 

Citiseries 
 Class 2017-A6 Notes 
 Issuer Certificate 

Pursuant to Sections 202 and 301(h) of the Indenture 

Reference is made to the Second Amended and Restated Indenture dated as of September 26, 2000, as amended and restated as of
August 9, 2011, and as further amended and restated as of November 10, 2016, between Citibank Credit Card Issuance Trust (the “Issuer”) and Deutsche Bank Trust Company Americas, as trustee (as so further amended and restated, the
“Indenture”). Capitalized terms used herein that are not otherwise defined have the meanings set forth in the Indenture. All references herein to designated Sections are to the designated Sections of the Indenture. 

Section 301(h) provides that the Issuer may from time to time create a tranche of Notes either by or pursuant to an Issuer Certificate setting
forth the principal terms thereof. Pursuant to this Issuer Certificate, there is hereby created a tranche of Notes having the following terms: 
 Series
Designation: Citiseries. This series is included in Group 1. 
 Tranche Designation: $775,000,000 Floating Rate
Class 2017-A6 Notes of May 2027 (Legal Maturity Date May 2029) (hereinafter, the “Class 2017-A6 Notes”) 

Currency: The Class 2017-A6 Notes will be payable, and denominated, in Dollars. 

Denominations: The Class 2017-A6 Notes will be issuable in minimum denominations of $100,000 and multiples
of $1,000 in excess of that amount. 
 Issuance Date: May 22, 2017 

Initial Principal Amount: $775,000,000 
 Issue
Price: 100% 
 Interest Rate: The Class 2017-A6 Notes will accrue interest with respect to any
interest period at a per annum rate equal to the Class 2017-A6 Note Rate for such interest period, calculated on the basis of the actual number of days in such interest period divided by 360. The “Class 2017-A6 Note Rate” means, with respect to the first interest period, [To Be Determined on May 18, 2017]% per annum and, with respect to each interest period thereafter, a per annum rate
equal to LIBOR for such interest period plus 0.77%. 
 The Issuer will determine LIBOR for each applicable interest period on the second business day before
the beginning of that interest period. For purposes of calculating LIBOR, a business day is any day on which dealings in deposits in U.S. Dollars are transacted in the London interbank market. 

 “LIBOR” means, as of any date of determination, the rate for deposits in U.S. Dollars for the
Designated Maturity (commencing on the first day of the relevant interest period) which appears on the Reuters Screen LIBOR01 Page as of 11:00 a.m., London time, on such date. If such rate does not appear on the Reuters Screen LIBOR01 Page, the rate
for that day will be determined on the basis of the rates at which deposits in U.S. Dollars are offered by the Reference Banks at approximately 11:00 a.m., London time, on that day to prime banks in the London interbank market for the Designated
Maturity (commencing on the first day of the relevant interest period). The Issuer will request the principal London office of each of the Reference Banks to provide a quotation of its rate. If at least two such quotations are provided, the rate for
that day will be the arithmetic mean of the quotations. If fewer than two quotations are provided as requested, the rate for that day will be the arithmetic mean of the rates quoted by major banks in New York City, selected by the Issuer, at
approximately 11:00 a.m., New York City time, on that day for loans in U.S. Dollars to leading European banks for a period of the Designated Maturity (commencing on the first day of the relevant interest period). 

“Reuters Screen LIBOR01 Page” means the display page currently so designated on the Reuters Monitor Money Rates service (or such other page
as may replace that page on that service or any successor service for the purpose of displaying comparable rates or prices). 
 “Designated
Maturity” means one month. 
 “Reference Banks” means four major banks in the London interbank market selected by the Issuer. 

Scheduled Interest Payment Dates: The 14th day of each month, beginning July 2017. 

Each payment of interest on the Class 2017-A6 Notes will include all interest accrued from and including the
preceding Interest Payment Date — or, for the first interest period, from and including the Issuance Date — to and including the day preceding the current Interest Payment Date, plus any interest accrued but not previously paid. 

The first deposit targeted to be made to the Interest Funding sub-Account for the
Class 2017-A6 Notes will be on the July 13, 2017 Interest Deposit Date and in an amount equal to $[To Be Determined on May 18, 2017]. 

Expected Principal Payment Date: May 14, 2027 

Legal Maturity Date: May 14, 2029 
 Monthly
Principal Date: For the month in which the Expected Principal Payment Date occurs, May 14, 2027, and for each other month, the 14th day of such month, or if such day is not a Business Day, the next following Business Day. 

Required Subordinated Amount of Class B Notes: $46,367,552.50 

  
 2 

 Required Subordinated Amount of Class C Notes: $61,823,377.50 

Controlled Accumulation Amount: $64,583,333.33 
 Form
of Notes: The Class 2017-A6 Notes will be issued as Global Notes. The Global Notes will initially be registered in the name of Cede & Co., as nominee of The Depository Trust Company, and will
be exchangeable for individual Notes only in accordance with the provisions of Section 204(c). 
 Additional Issuances of Class 2017-A6 Notes: The Issuer may at any time and from time to time issue additional Class 2017-A6 Notes, subject to the satisfaction of (i) the conditions
precedent set forth in Section 311(a) and (ii) the following conditions: 
  

	 	(a)	The Issuer has obtained written confirmation from each Rating Agency that there will be no Ratings Effect with respect to the then outstanding Class 2017-A6 Notes as a result
of the issuance of such additional Class 2017-A6 Notes; 

  

	 	(b)	As of the date of issuance of the additional Class 2017-A6 Notes, all amounts due and owing to the Holders of the then outstanding
Class 2017-A6 Notes have been paid and there is no Nominal Liquidation Amount Deficit with respect to the then outstanding Class 2017-A6 Notes;

  

	 	(c)	The additional Class 2017-A6 Notes will be fungible with the original Class 2017-A6 Notes for federal income tax purposes;

  

	 	(d)	If Holders of the then outstanding Class 2017-A6 Notes have the benefit of a Derivative Agreement, the Issuer will have obtained a Derivative Agreement for the benefit of the
Holders of the additional Class 2017-A6 Notes; and 

  

	 	(e)	The ratio of the Controlled Accumulation Amount to the Initial Dollar Principal Amount of the Class 2017-A6 Notes, including the additional
Class 2017-A6 Notes, will be equal to the ratio of the Controlled Accumulation Amount (before giving effect to the additional issuance) to the Initial Dollar Principal Amount of the Class 2017-A6 Notes, excluding the additional Class 2017-A6 Notes. 

As of the date of issuance of additional Class 2017-A6 Notes, the Outstanding Dollar Principal Amount and Nominal
Liquidation Amount of the Class 2017-A6 Notes will be increased to reflect the Initial Dollar Principal Amount of the additional Class 2017-A6 Notes. 

Any outstanding Class 2017-A6 Notes and any additional Class 2017-A6
Notes will be equally and ratably entitled to the benefits of the Indenture without preference, priority or distinction. 
 Optional Redemption
Provisions other than Section 1202 “Clean-Up Call”: None 

  
 3 

 Additional Early Redemption Events or changes to Early Redemption Events: None 

Additional Events of Default or changes to Events of Default: None 

Business Day: means any day other than (a) a Saturday or Sunday or (b) any other day on which national banking associations or state banking
institutions in New York, New York or South Dakota, or any other state in which the principal executive offices of any Additional Seller are located, are authorized or obligated by law, executive order or governmental decree to be closed. 

Securities Exchange Listing: None 

  
 4 

 The Class 2017-A6 Notes shall have such other terms
as are set forth in the form of Note attached hereto as Exhibit A. Pursuant to Section 202, the form of Note attached hereto has been approved by the Issuer. 

 

			
	CITIBANK CREDIT CARD ISSUANCE TRUST
		
	By	 	Citibank, N.A.,
		 	as Managing Beneficiary
	
	  

		 	[Name]
		 	[Title]

 Dated: May 22, 2017 

  
 5 

 Citiseries 

Class 2017-A6 Notes 

Reference is made to the resolutions adopted by the Board of Directors of Citibank, N.A. on January 25, 2017. The resolutions authorize
Citibank, N.A. from time to time to issue and sell, or to arrange for or participate in the issuance and sale of, one or more series and/or classes of pass-through certificates, participation certificates, commercial paper, notes, bonds or other
securities representing ownership interests in, or backed or secured by, pools of credit card receivables or interests therein (the “Receivables”) in an aggregate principal amount such that up to $45,000,000,000 of such certificates,
commercial paper, notes, bonds or other securities are outstanding at any one time and to sell, transfer, convey, assign or pledge or grant a security interest in all or any portion of its Receivables to Citibank Credit Card Master Trust I, Citibank
Omni Trust or any direct or indirect subsidiaries of Citibank, N.A., affiliates of Citigroup Inc., additional trusts or other entities or trustees in connection therewith on such terms as to be determined by the Citibank, N.A. Securitization Pricing
and Loan Committee (the “Pricing and Loan Committee”). 
 The undersigned, a duly authorized member of the Pricing and Loan
Committee, on behalf of such Pricing and Loan Committee, does hereby certify that the preceding Issuer Certificate, the terms of the tranche of Notes set forth in and to be created by the Issuer Certificate and the increase in the Invested Amount of
the Collateral Certificate resulting from the issuance of such Notes have been approved by such Pricing and Loan Committee. In addition, the following underwriting/selling agent terms with respect to this tranche of Notes have been approved by the
Pricing and Loan Committee: 
 Issue Price: 100% 

Underwriting Commission: 0.350% 

Proceeds to Issuer: 99.650% 

Representative of the Underwriters: Citigroup Global Markets Inc. 

The preceding Issuer Certificate and this certification of Pricing and Loan Committee approval shall be, continuously from the time of their
execution, official records of Citibank, N.A. 
  

	
	  

	[Name]
	Member of the Securitization Pricing and Loan Committee
	 Citibank, N.A.

 Dated: May 22, 2017 

  
 6 

 Exhibit A 

FORM OF 
 CITISERIES 

FLOATING RATE CLASS 2017-A6 NOTES OF MAY 2027 

(Legal Maturity Date May 2029) 
  

			
	$[    ],000,000	  	REGISTERED        
	CUSIP No. 17305E GE9	  	No. R-[1][2]

 UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK
CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 THE PRINCIPAL OF THIS NOTE IS PAYABLE AS SET FORTH HEREIN AND IN THE
INDENTURE REFERRED TO BELOW. ACCORDINGLY, THE OUTSTANDING PRINCIPAL AMOUNT OF THIS NOTE AT ANY TIME MAY BE LESS THAN THE AMOUNT SHOWN ON THE FACE HEREOF. 

CITIBANK CREDIT CARD ISSUANCE TRUST 

CITISERIES 
 FLOATING RATE CLASS 2017-A6 NOTES OF MAY 2027 
 (Legal Maturity Date May 2029) 

CITIBANK CREDIT CARD ISSUANCE TRUST, a trust formed and existing under the laws of the State of Delaware (including any successor, the “Issuer”),
for value received, hereby promises to pay to CEDE & CO., or its registered assigns, the principal amount of [    ] HUNDRED MILLION DOLLARS ($[    ],000,000). The Expected Principal Payment Date for
this Note is May 14, 2027. The Legal Maturity Date for this Note is May 14, 2029. 
 The Issuer hereby promises to pay interest on this Note on
the 14th day of each month, beginning July 2017, until the principal of this Note is paid or made available for payment, subject to certain limitations set forth in the Indenture. Interest will accrue on the outstanding principal amount of this Note
for each interest period in an amount equal to the product of (i) the actual 

 
number of days in such interest period divided by 360, (ii) a rate per annum equal to the Class 2017-A6 Note Rate for such interest period, and
(iii) the outstanding principal amount of this Note as of the preceding Interest Payment Date (after giving effect to any payments of principal made on the preceding Interest Payment Date) or, with respect to the first Interest Payment Date,
the initial principal amount of this Note. The Class 2017-A6 Note Rate will be determined as provided in the Indenture. 

If any Interest Payment Date or Principal Payment Date of this Note falls on a day that is not a Business Day, the required payment of interest or principal
will be made on the following Business Day. 
 This Note is one of the Citiseries, Class 2017-A6 Notes issued
pursuant to the Second Amended and Restated Indenture dated as of September 26, 2000, as amended and restated as of August 9, 2011, and as further amended and restated as of November 10, 2016 (as so further amended and restated and
otherwise modified from time to time, the “Indenture”) between the Issuer and Deutsche Bank Trust Company Americas, as Trustee. For purposes of this Note, the term “Indenture” includes any supplemental indenture or Issuer
Certificate relating to the Citiseries, Class 2017-A6 Notes. This Note is subject to all of the terms of the Indenture. All terms used in this Note that are not otherwise defined herein and that are
defined in the Indenture will have the meanings assigned to them therein. 
 The principal of and interest on this Note are payable in such coin or currency
of the United States of America as at the time of payment is legal tender for payment of public and private debts. 
 Reference is made to the further
provisions of this Note set forth on the reverse hereof, which will have the same effect as though fully set forth on the face of this Note. 
 Unless the
certificate of authentication hereon has been executed by the Trustee whose name appears below by manual signature, this Note will not be entitled to any benefit under the Indenture, or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Issuer has caused this instrument to be signed, manually or in facsimile, by an Issuer
Authorized Officer. 
  

					
	CITIBANK CREDIT CARD ISSUANCE TRUST
		
	By:	 	CITIBANK, N.A.,
		 	 as Managing Beneficiary of
 Citibank
Credit Card Issuance Trust

			
		 	By:	 	  

		 		 	[Name]
		 		 	[Title]

 Dated: May 22, 2017 

TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

This is one of the Notes designated above and referred to in the within mentioned Indenture. 

 

			
	DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee under the Indenture
		
	By:	 	  

		 	Authorized Signatory

 Dated: May 22, 2017 

 REVERSE OF NOTE 

This Note is one of a duly authorized issue of Notes of the Issuer, designated as its Citiseries Floating Rate
Class 2017-A6 Notes of May 2027 (Legal Maturity Date May 2029) (herein called the “Notes”), all issued under an Indenture, to which Indenture reference is hereby made for a statement of the
respective rights and obligations thereunder of the Issuer, the Trustee and the Holders of the Notes. 
 This Note ranks pari passu with all other
Class A Notes of the same series, as set forth in the Indenture. This Note is secured to the extent, and by the collateral, described in the Indenture. 

The Issuer will pay interest on overdue interest as set forth in the Indenture to the extent lawful. 

Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a beneficial interest in this Note, agrees that
no recourse may be taken, directly or indirectly, with respect to the obligations of the Issuer or the Trustee on the Notes, against the Issuer, the Issuer Trustee, Citibank, N.A., the Trustee or any affiliate, officer, employee or director of any
of them, and the obligation of the Issuer to pay principal of or interest on this Note or any other amount payable to the Holder of this Note will be subject to Article V of the Indenture. 

Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a beneficial interest in this Note, in each case
other than Citibank, N.A. as Holder or owner, agrees that this Note is intended to be debt of Citibank, N.A. for federal, state and local income and franchise tax purposes, and agrees to treat this Note accordingly for all such purposes, unless
otherwise required by a taxing authority. 
 Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a
beneficial interest in this Note, agrees that it will not at any time institute against the Issuer, or join in any institution against the Issuer of, any bankruptcy, reorganization, arrangement, insolvency or liquidation proceeding, or other
proceedings under any United States federal or state bankruptcy or similar law in connection with any obligations relating to this Note, the Indenture or any Derivative Agreement. 

This Note and the Indenture will be construed in accordance with and governed by the laws of the State of New York. 

Certain amendments may be made to the Indenture without the consent of the Holder of this Note. This Note must be surrendered for final payment of principal
and interest. 

 ASSIGNMENT 

Social Security or taxpayer I.D. or other identifying number of assignee:
                                         

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto 
  

	
	  

	
	  

	(name and address of assignee)

 the within Note and all rights thereunder, and hereby irrevocably constitutes and appoints
                                        ,
attorney, to transfer said Note on the books kept for registration thereof, with full power of substitution in the premises. 
  

									
	Dated:	 	  
	 		 	  
	 	*
		 		 		 	Signature Guaranteed:	 	

  

	*	NOTE: The signature to this assignment must correspond with the name of the registered owner as it appears on the face of the within Note in every particular without alteration, enlargement or any change whatsoever.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]